Liver steatosis adverse outcome pathway (WP4010)

Homo sapiens

Open in new tab Open in NDEx Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
This liver steatosis AOP starts from the top with different molecular initiating events going down towards liver steatosis. The black nodes are Key Events and green nodes are molecular pathways. Adverse outcome pathway liver steatosis; the accumulation of lipids in hepatocytes, caused either by over-nutrition, visceral obesity, metabolic syndrome, or environmental toxins. Liver steatosis can be divided into three main categories: alcoholic liver disease (ALD), non-alcoholic liver disease (NAFLD), and toxicant-associated liver disease (TAFLD).[https://pubmed.ncbi.nlm.nih.gov/28210688/ Review on liver steatosis]

Authors

JJv Heijden , Alex Pico , Marvin Martens , Jeroen Kearns , Chesley De Windt , Eric Weitz , Finterly Hu , MysticArchers , Martina Summer-Kutmon , and Kristina Hanspers

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Adverse Outcome Pathways

Annotations

Cell Type Ontology

hepatocyte

Disease Ontology

fatty liver disease

Pathway Ontology

disease pathway

Participants

Label Type Compact URI Comment

References

  1. Description of Prototype Modes-of-action Related to Repeated Dose Toxicity [Internet]. 2012. 40 p. Available from: https://books.google.com/books/about/Description_of_Prototype_Modes_of_action.html?hl=&id=fpFBzQEACAAJ OpenLibrary Worldcat
  2. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Nebert DW, Petersen DD, Puga A. Pharmacogenetics. 1991 Nov;1(2):68–78. PubMed Europe PMC Scholia
  3. The human CYP1A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports AH-receptor binding and promoter-specific induction. Quattrochi LC, Vu T, Tukey RH. J Biol Chem. 1994 Mar 4;269(9):6949–54. PubMed Europe PMC Scholia
  4. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, et al. J Biol Chem. 1996 Nov 8;271(45):28324–30. PubMed Europe PMC Scholia
  5. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Kolluri SK, Weiss C, Koff A, Göttlicher M. Genes Dev. 1999 Jul 1;13(13):1742–53. PubMed Europe PMC Scholia
  6. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, et al. Hepatology. 2001 May;33(5):1232–8. PubMed Europe PMC Scholia
  7. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Shimada T, Oda Y, Gillam EM, Guengerich FP, Inoue K. Drug Metab Dispos. 2001 Sep;29(9):1176–82. PubMed Europe PMC Scholia
  8. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, et al. J Biol Chem. 2003 May 9;278(19):17277–83. PubMed Europe PMC Scholia
  9. The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. Maglich JM, Watson J, McMillen PJ, Goodwin B, Willson TM, Moore JT. J Biol Chem. 2004 May 7;279(19):19832–8. PubMed Europe PMC Scholia
  10. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Kodama S, Koike C, Negishi M, Yamamoto Y. Mol Cell Biol. 2004 Sep;24(18):7931–40. PubMed Europe PMC Scholia
  11. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Handschin C, Meyer UA. Arch Biochem Biophys. 2005 Jan 15;433(2):387–96. PubMed Europe PMC Scholia
  12. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JRB, et al. Diabetes. 2006 Aug;55(8):2159–70. PubMed Europe PMC Scholia
  13. The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. Echchgadda I, Song CS, Oh T, Ahmed M, De La Cruz IJ, Chatterjee B. Mol Endocrinol. 2007 Sep;21(9):2099–111. PubMed Europe PMC Scholia
  14. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Pavek P, Dvorak Z. Curr Drug Metab. 2008 Feb;9(2):129–43. PubMed Europe PMC Scholia
  15. Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Hariparsad N, Chu X, Yabut J, Labhart P, Hartley DP, Dai X, et al. Nucleic Acids Res. 2009 Mar;37(4):1160–73. PubMed Europe PMC Scholia
  16. From differential induction of UDP-glucuronosyltransferases in rat liver to characterization of responsible ligand-activated transcription factors, and their multilevel crosstalk in humans. Bock KW. Biochem Pharmacol. 2011 Jul 1;82(1):9–16. PubMed Europe PMC Scholia
  17. Crosstalk of thyroid hormone receptor and liver X receptor in lipid metabolism and beyond [Review]. Hashimoto K, Mori M. Endocr J. 2011;58(11):921–30. PubMed Europe PMC Scholia
  18. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Mellor CL, Steinmetz FP, Cronin MTD. Crit Rev Toxicol. 2016 Feb;46(2):138–52. PubMed Europe PMC Scholia